IL164376A0 - Ox4or binding agents, their preparation and pharmaceutical compositions containing them - Google Patents
Ox4or binding agents, their preparation and pharmaceutical compositions containing themInfo
- Publication number
- IL164376A0 IL164376A0 IL16437602A IL16437602A IL164376A0 IL 164376 A0 IL164376 A0 IL 164376A0 IL 16437602 A IL16437602 A IL 16437602A IL 16437602 A IL16437602 A IL 16437602A IL 164376 A0 IL164376 A0 IL 164376A0
- Authority
- IL
- Israel
- Prior art keywords
- ox4or
- preparation
- pharmaceutical compositions
- compositions containing
- binding agents
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02100334 | 2002-04-03 | ||
| PCT/EP2003/050089 WO2003082919A2 (en) | 2002-04-03 | 2003-04-02 | Ox40r binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164376A0 true IL164376A0 (en) | 2005-12-18 |
Family
ID=28459562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16437602A IL164376A0 (en) | 2002-04-03 | 2002-04-03 | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7758852B2 (ja) |
| EP (1) | EP1492813B1 (ja) |
| JP (1) | JP4426315B2 (ja) |
| AR (1) | AR039231A1 (ja) |
| AT (1) | ATE557036T1 (ja) |
| AU (1) | AU2003240761B2 (ja) |
| CA (1) | CA2480694A1 (ja) |
| ES (1) | ES2387767T3 (ja) |
| IL (1) | IL164376A0 (ja) |
| WO (1) | WO2003082919A2 (ja) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ546552A (en) | 2003-10-17 | 2009-10-30 | Baylor College Medicine | A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis |
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| WO2007133290A2 (en) | 2005-12-16 | 2007-11-22 | Genentech, Inc. | Anti-ox40l antibodies and methods using same |
| US20110008368A1 (en) * | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
| US20110028688A1 (en) * | 2006-06-21 | 2011-02-03 | Genentech, Inc. | Crystal structure of ox40l and ox40l complexed with ox40 receptor |
| US9347947B2 (en) * | 2009-03-12 | 2016-05-24 | Siemens Healthcare Diagnostics Inc. | Immunoassays employing non-particulate chemiluminescent reagent |
| ES2630328T3 (es) | 2010-08-23 | 2017-08-21 | Board Of Regents, The University Of Texas System | Anticuerpos anti-OX40 y procedimientos de uso de los mismos |
| CA2845810C (en) * | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US10696946B2 (en) | 2013-02-22 | 2020-06-30 | The Board Of Trustees Of The University Of Illinois | T-REG cell expansion |
| US20140294792A1 (en) * | 2013-02-22 | 2014-10-02 | The Board Of Trustees Of The University Of Illinois | T-REG Cell Expansion |
| JP2017165652A (ja) * | 2014-06-30 | 2017-09-21 | 国立大学法人東北大学 | 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬 |
| WO2016008976A1 (en) | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
| KR102504758B1 (ko) | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| EP3253876B1 (en) | 2015-02-06 | 2020-11-04 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| EP4015537A1 (en) | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| EP3366691A1 (en) | 2015-12-03 | 2018-08-29 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| KR102527786B1 (ko) | 2016-04-07 | 2023-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조정제로서 유용한 헤테로시클릭 아미드 |
| CA3019628A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| JP2019516685A (ja) | 2016-05-05 | 2019-06-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｚｅｓｔｅホモログ２阻害剤のエンハンサー |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
| WO2018071405A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
| KR20190090822A (ko) | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 조합 요법 |
| AU2017369994A1 (en) | 2016-12-01 | 2019-06-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| US11192933B2 (en) * | 2017-02-27 | 2021-12-07 | Shattuck Labs, Inc. | VSIG8-based chimeric proteins |
| CN110573504A (zh) | 2017-02-27 | 2019-12-13 | 葛兰素史克知识产权开发有限公司 | 作为激酶抑制剂的杂环酰胺 |
| US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
| BR112019025257A2 (pt) | 2017-06-09 | 2020-09-29 | Glaxosmithkline Intellectual Property Development Limited | método para tratar câncer, e, anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo |
| BR112019025913A2 (pt) | 2017-06-09 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira. |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
| WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | GENERATOR STIMULATOR MODULATORS (STING) INTERFERON |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| WO2020160375A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof |
| KR20220026585A (ko) | 2019-06-26 | 2022-03-04 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Il1rap 결합 단백질 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| EP4034562A2 (en) | 2019-09-27 | 2022-08-03 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins |
| CA3167689A1 (en) | 2020-01-28 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| BR112023017296A2 (pt) | 2021-03-02 | 2023-11-14 | Glaxosmithkline Ip Dev Ltd | Piridinas substituídas como inibidores de dnmt1 |
| EP4314060A1 (en) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106197A (en) * | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6602856B1 (en) * | 1995-01-17 | 2003-08-05 | J. Mark Quillan | Antagonists of alpha-melanocyte stimulating hormone and methods based thereon |
| US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| EP1171626A4 (en) * | 1999-03-26 | 2002-10-30 | Human Genome Sciences Inc | FIFTY HUMAN SECRETED PROTEINS |
| US6872519B1 (en) * | 1999-04-27 | 2005-03-29 | Mirus Bio Corporation | In vitro process for selecting phage resistant to blood inactivation |
| GB2373500B (en) | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| CA2402780A1 (en) * | 2000-03-29 | 2001-10-04 | Dgi Biotechnologies, L.L.C. | Insulin and igf-1 receptor agonists and antagonists |
-
2002
- 2002-04-03 IL IL16437602A patent/IL164376A0/xx unknown
-
2003
- 2003-04-02 AU AU2003240761A patent/AU2003240761B2/en not_active Ceased
- 2003-04-02 ES ES03730172T patent/ES2387767T3/es not_active Expired - Lifetime
- 2003-04-02 JP JP2003580382A patent/JP4426315B2/ja not_active Expired - Fee Related
- 2003-04-02 US US10/510,015 patent/US7758852B2/en not_active Expired - Fee Related
- 2003-04-02 WO PCT/EP2003/050089 patent/WO2003082919A2/en active Application Filing
- 2003-04-02 AR ARP030101155A patent/AR039231A1/es not_active Application Discontinuation
- 2003-04-02 EP EP03730172A patent/EP1492813B1/en not_active Expired - Lifetime
- 2003-04-02 CA CA002480694A patent/CA2480694A1/en not_active Abandoned
- 2003-04-02 AT AT03730172T patent/ATE557036T1/de active
-
2009
- 2009-11-24 US US12/624,534 patent/US7858765B2/en not_active Expired - Fee Related
-
2010
- 2010-11-23 US US12/952,226 patent/US20110086057A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR039231A1 (es) | 2005-02-09 |
| US7758852B2 (en) | 2010-07-20 |
| ES2387767T3 (es) | 2012-10-01 |
| US20110086057A1 (en) | 2011-04-14 |
| AU2003240761B2 (en) | 2009-04-23 |
| CA2480694A1 (en) | 2003-10-09 |
| JP4426315B2 (ja) | 2010-03-03 |
| US7858765B2 (en) | 2010-12-28 |
| US20070009964A1 (en) | 2007-01-11 |
| JP2006506041A (ja) | 2006-02-23 |
| AU2003240761A1 (en) | 2003-10-13 |
| WO2003082919A2 (en) | 2003-10-09 |
| EP1492813A2 (en) | 2005-01-05 |
| ATE557036T1 (de) | 2012-05-15 |
| WO2003082919A3 (en) | 2004-02-05 |
| EP1492813B1 (en) | 2012-05-09 |
| US20100136628A1 (en) | 2010-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL164376A0 (en) | Ox4or binding agents, their preparation and pharmaceutical compositions containing them | |
| IL173195A0 (en) | Cyclovinylazoline derivatives, their preparation and pharmaceutical compositions containing them | |
| HUP0400467A3 (en) | 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use | |
| HUP0204514A3 (en) | Pyridinylimidazoles, pharmaceutical compositions containing them and their use | |
| HUP0402566A3 (en) | C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them | |
| HUP0301573A3 (en) | Substituted arylpyrazines, pharmaceutical compositions containing them and their use | |
| ZA200702226B (en) | Compounds, compositions containing them, preparations thereof and uses thereof II | |
| AU2003291103A8 (en) | Pharmaceutical composition | |
| HUP0204081A3 (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
| IL164547A0 (en) | Pharmaceutical composition | |
| HUP0400967A3 (en) | Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them | |
| IL183044A0 (en) | 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof | |
| HUP0203194A3 (en) | Phenylpiperazines, pharmaceutical compositions containing them and their use | |
| HUP0203735A3 (en) | 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
| AU2003250372A8 (en) | Pharmaceutical composition | |
| HUP0500024A3 (en) | 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them | |
| HUP0400179A3 (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them | |
| IL173198A0 (en) | Hydrazide derivatives, their preparation and pharmaceutical compositions containing them | |
| HUP0303469A3 (en) | Phtalazinon-derivatives, their use and pharmaceutical compositions containing them | |
| HUP0303593A3 (en) | Biguanide derivatives, pharmaceutical compositions containing them and their use | |
| HUP0401644A3 (en) | Aminobenzoephenones, pharmaceutical compositions containing them and use thereof | |
| HUP0401713A3 (en) | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | |
| PL374761A1 (en) | N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them | |
| IL173507A0 (en) | Chimeric proteins, their preparation and pharmaceutical compositions containing them | |
| HK1065477A1 (en) | Pharmaceutical composition |